CD274 and neoplasm: Palbociclib was reported to enhance the anti-tumor activity of anti-PD-1/PD-L1 ICIs by stimulating the tumor production of type III interferons (IFNs) and increasing tumor cell surface expression of MHC class I proteins [103].